急诊科患者新型强效阿片类药物与芬太尼过量时纳洛酮的使用
本研究为正在进行的全国性ToxIC Fentalog队列研究(2020至2022年)的子组分析,纳入急诊就诊且疑似急性阿片类药物过量、留有残余血样的成人,分析其中确证新型强效阿片类药物(NPO,如溴咯啶、异硝西泮、美托尼他嗪和/或N-哌啶基依托尼他嗪)阳性的患者,并与仅芬太尼阳性且毒理学分析无其他分析物的患者比较。主要结局为常规临床诊疗中纳洛酮总推注次数和总累积剂量。结果显示,NPO组院内纳洛酮平均推注次数为1.33(SD 1.50)次,显著高于芬太尼组的0.36(SD 0.92)次(P=0.02),效应量Cohen d=0.78;美托尼他嗪过量与心脏骤停相关,2例美托尼他嗪过量患者均接受了心肺复苏,平均纳洛酮剂量为3.0(SD 0)次。作者认为需进一步研究确认这些初步关联。
要点
- NPO组院内纳洛酮平均推注次数为1.33(SD 1.50)次,芬太尼组为0.36(SD 0.92)次,差异有统计学意义(P=0.02),效应量Cohen d=0.78。
- 美托尼他嗪过量与心脏骤停相关,2例美托尼他嗪过量患者(100%)均接受了心肺复苏。
- 美托尼他嗪病例平均纳洛酮推注次数为3.0(SD 0)次,高于NPO组总体水平。
- 在537例完成实验室检测数据的患者中,仅芬太尼阳性11例(2.0%),NPO阳性9例(1.7%)。
- 作者结论认为,确诊NPO过量的急诊患者院内纳洛酮用量高于仅芬太尼阳性者,需进一步研究确认这些初步关联。
适用人群与场景
- 纳入:2020至2022年ToxIC Fentalog队列研究中急诊就诊、疑似急性阿片类药物过量且留有残余血样的成人,确证检测NPO分析物(溴咯啶、异硝西泮、美托尼他嗪和/或N-哌啶基依托尼他嗪)阳性者。
- 对照:芬太尼阳性且毒理学分析无其他分析物的患者。
- NPO组年龄20至57岁,4例男性(44.4%)、5例女性(55.6%)。
红旗征与不能漏的情况
- 美托尼他嗪过量与心脏骤停相关,2例美托尼他嗪过量患者(100%)接受了心肺复苏。
研究设计与关键结果
- 研究类型:正在进行的全国性ToxIC Fentalog队列研究(2020至2022年)的子组分析。
- 筛查2298例,717例符合纳入标准,537例有完整实验室检测数据;仅芬太尼阳性11例(2.0%),NPO阳性9例(1.7%)。
- 主要结局:NPO组院内纳洛酮平均推注次数1.33(SD 1.50)次,芬太尼组0.36(SD 0.92)次,差异有统计学意义(P=0.02),效应量Cohen d=0.78。
- 美托尼他嗪过量与心脏骤停相关,且总体纳洛酮剂量更多;美托尼他嗪病例平均纳洛酮推注次数3.0(SD 0)次,2例美托尼他嗪过量患者(100%)接受了心肺复苏。
证据类型、等级与局限
- 证据类型:队列研究的子组分析。
- 局限:作者指出需进一步研究确认这些初步关联。
对床旁实践的改变
- 作者结论认为,确诊NPO过量的急诊患者院内纳洛酮用量高于仅芬太尼阳性者;需进一步研究确认这些初步关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Synthetic opioids, such as the fentanyl analogue and nitazene drug class, are among the fastest growing types of opioids being detected in patients in the emergency department (ED) with illicit opioid overdose (OD). However, clinical outcomes from OD of novel potent opioids (NPOs), specifically nitazenes, are unknown aside from small case series.
OBJECTIVE: To determine naloxone administration and clinical sequelae of patients who were in the ED with NPO overdose compared with fentanyl OD.
DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study subgroup analysis of adults admitted to the ED and tested positive for NPOs among in the ongoing nationwide ToxIC Fentalog cohort study from 2020 to 2022. Patients who were in the ED with a presumed acute opioid OD and residual blood samples were included, and those testing positive for NPOs were analyzed. Patients were included in this analysis if their confirmatory testing was positive for an NPO analyte, such as brorphine, isotonitazene, metonitazene, and/or N-piperidinyl etonitazene. A comparison group included patients that were positive for fentanyl and devoid of any other analytes on toxicologic analysis.
EXPOSURES: Patients were exposed to NPOs, including brorphine, isotonitazene, metonitazene and/or N-piperidinyl etonitazene.
MAIN OUTCOMES AND MEASURES: The primary outcome was the total number of naloxone doses and total cumulative naloxone dose administered as part of routine clinical care following the OD. Naloxone requirements and clinical sequelae of NPO-positive patients were compared with those testing positive for fentanyl only.
RESULTS: During the study period, 2298 patients were screened, of whom 717 met inclusion criteria, 537 had complete laboratory testing data, with 11 (2.0%) positive for only fentanyl and 9 (1.7%) positive for NPOs (brorphine, isotonitazene, metonitazene, or N-piperidinyl etonitazene). The age range of patients was aged 20 to 57 years (4 males [44.4%] and 5 females [55.6%]). The NPO group received a statistically significantly higher mean (SD) number of naloxone boluses in-hospital (1.33 [1.50]) compared with the fentanyl group (0.36 [0.92]) (P = .02), which corresponded to a moderately large effect size (Cohen d = 0.78). Metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. Metonitazene cases had a mean (SD) number of 3.0 (0) naloxone doses, and 2 of 2 patients (100%) with metonitazene overdoses were administered cardiopulmonary resuscitation.
CONCLUSIONS AND RELEVANCE: In this cohort study of patients admitted to the ED with confirmed opioid overdose testing positive for NPOs, in-hospital naloxone dosing was high compared with patients who tested positive for fentanyl alone. Further study is warranted to confirm these preliminary associations.
参考来源
- Amaducci A, Aldy K, Campleman SL, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Netw Open. 2023. PMID: 37642962. doi:10.1001/jamanetworkopen.2023.31264
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。